Royalty Pharma PLC (NASDAQ:RPRX) Receives Average Recommendation of “Moderate Buy” from Brokerages

Royalty Pharma PLC (NASDAQ:RPRX) has received an average rating of “Moderate Buy” from the six research firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $45.60.

Several equities analysts recently issued reports on RPRX shares. Wall Street Zen lowered shares of Royalty Pharma from a “strong-buy” rating to a “buy” rating in a report on Friday, November 28th. Morgan Stanley dropped their target price on Royalty Pharma from $55.00 to $54.00 and set an “overweight” rating on the stock in a research report on Friday, October 10th. TD Cowen lifted their price target on Royalty Pharma from $42.00 to $45.00 and gave the company a “buy” rating in a report on Thursday, December 11th. Weiss Ratings cut Royalty Pharma from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Saturday, October 25th. Finally, Leerink Partners set a $45.00 price objective on Royalty Pharma in a research report on Thursday, December 11th.

Insider Transactions at Royalty Pharma

In related news, EVP Marshall Urist sold 23,334 shares of the business’s stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $39.15, for a total transaction of $913,526.10. Following the completion of the transaction, the executive vice president owned 160,000 shares in the company, valued at $6,264,000. The trade was a 12.73% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Terrance P. Coyne sold 69,594 shares of the stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $39.30, for a total transaction of $2,735,044.20. Following the sale, the chief financial officer directly owned 54,760 shares of the company’s stock, valued at $2,152,068. The trade was a 55.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 826,511 shares of company stock valued at $32,224,604 in the last 90 days. Insiders own 18.90% of the company’s stock.

Institutional Trading of Royalty Pharma

Institutional investors have recently made changes to their positions in the business. Hudson Bay Capital Management LP raised its stake in Royalty Pharma by 1.0% in the third quarter. Hudson Bay Capital Management LP now owns 29,384 shares of the biopharmaceutical company’s stock valued at $1,037,000 after buying an additional 289 shares during the last quarter. Tudor Investment Corp ET AL grew its stake in shares of Royalty Pharma by 34.4% during the third quarter. Tudor Investment Corp ET AL now owns 863,835 shares of the biopharmaceutical company’s stock worth $30,476,000 after acquiring an additional 221,099 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Royalty Pharma by 28.1% during the third quarter. JPMorgan Chase & Co. now owns 1,759,620 shares of the biopharmaceutical company’s stock valued at $62,079,000 after acquiring an additional 386,108 shares in the last quarter. CIBC Bancorp USA Inc. purchased a new position in shares of Royalty Pharma in the 3rd quarter valued at approximately $480,000. Finally, Alpine Global Management LLC acquired a new stake in Royalty Pharma in the 3rd quarter worth approximately $513,000. Institutional investors and hedge funds own 54.35% of the company’s stock.

Royalty Pharma Stock Performance

RPRX stock opened at $39.39 on Wednesday. Royalty Pharma has a 1-year low of $25.01 and a 1-year high of $41.24. The business has a 50-day moving average price of $38.49 and a 200 day moving average price of $36.86. The company has a market capitalization of $22.74 billion, a P/E ratio of 29.84, a PEG ratio of 2.05 and a beta of 0.47. The company has a debt-to-equity ratio of 0.89, a current ratio of 3.48 and a quick ratio of 3.48.

Royalty Pharma (NASDAQ:RPRX) last posted its earnings results on Wednesday, November 5th. The biopharmaceutical company reported $1.17 EPS for the quarter, beating analysts’ consensus estimates of $1.11 by $0.06. Royalty Pharma had a net margin of 32.51% and a return on equity of 26.36%. The business had revenue of $609.29 million for the quarter, compared to the consensus estimate of $765.01 million. As a group, equities research analysts forecast that Royalty Pharma will post 4.49 EPS for the current fiscal year.

Royalty Pharma Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th were issued a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date was Friday, November 14th. Royalty Pharma’s dividend payout ratio (DPR) is currently 66.67%.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.